Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients

Braz J Infect Dis. 2015 Sep-Oct;19(5):529-32. doi: 10.1016/j.bjid.2015.03.005. Epub 2015 May 19.

Abstract

Antiretroviral therapy has significantly evolved in the last decade, with an increasing number of new drugs and classes. Currently, even heavily experienced patients can be successfully treated with new regimens. In Brazil, the recent incorporation of some new antiretroviral drugs made it possible to suppress HIV plasma viremia in most treated patients, with significant benefits in terms of quality of life and survival. However, little has been published on outcomes of patients under new drugs-based regimens. We reviewed the safety and efficacy of antiretroviral regimens using recently introduced drugs in Bahia. Our results confirm that patients using darunavir, raltegravir, enfuvirtide, or etravirine presented with a high rate of virological suppression without significant adverse events, after one year of follow-up.

Keywords: Antiretroviral; HIV; Salvage therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Brazil
  • CD4 Lymphocyte Count
  • Darunavir / therapeutic use
  • Drug Administration Schedule
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / therapeutic use
  • Humans
  • Male
  • Nitriles
  • Peptide Fragments / therapeutic use
  • Pyridazines / therapeutic use
  • Pyrimidines
  • Quality of Life
  • Raltegravir Potassium / therapeutic use
  • Salvage Therapy
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Envelope Protein gp41
  • Nitriles
  • Peptide Fragments
  • Pyridazines
  • Pyrimidines
  • etravirine
  • Enfuvirtide
  • Raltegravir Potassium
  • Darunavir